Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Garbe

Showing results (311-320 of 319) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 319 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countriesL Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countriesL Kandolf Sekulovic, J Guo, S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatmentsL Kandolf Sekulovic, K Peris, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 26, 2020
The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task ForceC Garbe, K Peris, E Soura, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 4, 2024
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by expertsC Gaudy-Marqueste, J J Grob, C Garbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
Pageof 32

Showing results (311-320 of 319) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 319 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countriesL Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countriesL Kandolf Sekulovic, J Guo, S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatmentsL Kandolf Sekulovic, K Peris, A Hauschild, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 26, 2020
The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task ForceC Garbe, K Peris, E Soura, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 4, 2024
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by expertsC Gaudy-Marqueste, J J Grob, C Garbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.
Pageof 32